Abstract
Objective:Undifferentiated inflammatory arthritis is one of the requirements for being diagnosed in the patient doesnt meet the classical criteria for recognized arthritis. which no approved treatment algorithm exist. Sulfasalazine and hydroxychloroquine used in this trial for early Undifferentiated inflammatory arthritis. Methods: A six-month, double-blind, randomized experiment was conducted. Undifferentiated arthritis in 100 consecutive patients. ESR, morning stiffness, number of swollen joints, and a pain score are all measured on a monthly basis. Patients with certain rheumatological diagnoses were excluded.. Results: The trial was completed by 74 patients.The sulfasalazine group patient responds better and more promptly. There have been respond in terms of grip strength, pain score, and the duration of morning stiffness compared to hydroxychloroquine.The 26 withdrawal from the research prematurely owing to side effects, with gastrointestinal symptoms being the primary cause in the actively treated group. Conclusions:Our statistics lead us to the conclusion that sulfasalazine provides an earlier and better response than hydroxychloroquine. The earlier Response to sulfasalazine is a significant benefit for patients quality of life.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
